Clinical Trial Update: A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A. [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing safety and efficacy of Optivate® in children under 6 with Haemophilia A has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Optivate (von Willebrand factor concentrate (plasma-derived))

Snippet

Sponsor: Bio Products Laboratory | Conditions: Haemophilia A | Phase 3 | Status: COMPLETED